litlas
Log inCreate account

James E. Balow

Active 1973–2020

Also published as
JAMES E. BALOW
67
Papers
23,217
Citations
66
h-index
67
i10-index

Citations

Citations per year for James E. Balow1974: 4 citations1975: 1 citations1976: 5 citations1977: 1 citations1978: 12 citations1979: 17 citations1980: 15 citations1981: 18 citations1982: 25 citations1983: 21 citations1984: 27 citations1985: 20 citations1986: 28 citations1987: 22 citations1988: 28 citations1989: 32 citations1990: 44 citations1991: 26 citations1992: 45 citations1993: 48 citations1994: 62 citations1995: 60 citations1996: 85 citations1997: 65 citations1998: 94 citations1999: 106 citations2000: 109 citations2001: 133 citations2002: 152 citations2003: 157 citations2004: 226 citations2005: 159 citations2006: 191 citations2007: 183 citations2008: 110 citations2009: 194 citations2010: 176 citations2011: 149 citations2012: 182 citations2013: 120 citations2014: 119 citations2015: 118 citations2016: 124 citations2017: 117 citations2018: 99 citations2019: 370 citations2020: 356 citations2021: 305 citations2022: 238 citations2023: 139 citations2024: 238 citations2025: 101 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,896 citing papers, 29% of this breakdownUnited Kingdom: 461 citing papers, 7% of this breakdownGermany: 400 citing papers, 6.1% of this breakdownChina: 384 citing papers, 5.9% of this breakdownItaly: 309 citing papers, 4.7% of this breakdownFrance: 289 citing papers, 4.4% of this breakdownCanada: 241 citing papers, 3.7% of this breakdownNetherlands: 214 citing papers, 3.3% of this breakdownSpain: 194 citing papers, 3% of this breakdownJapan: 193 citing papers, 2.9% of this breakdownAustralia: 138 citing papers, 2.1% of this breakdownSwitzerland: 126 citing papers, 1.9% of this breakdown
0%29%Other 26%

Institutions

Fields

  • Medicine66.4%
  • Biochemistry, Genetics and Molecular Biology18.7%
  • Immunology and Microbiology11.1%
  • Neuroscience1.5%
  • Pharmacology, Toxicology and Pharmaceutics0.7%
  • Computer Science0.3%
  • Other1.3%

Topics

  • Systemic Lupus Erythematosus Research11.4%
  • Renal Diseases and Glomerulopathies4.3%
  • Inflammasome and immune disorders3.2%
  • Lysosomal Storage Disorders Research3.2%
  • T-cell and B-cell Immunology3.1%
  • Renal Transplantation Outcomes and Treatments1.9%
  • Other72.9%

Coauthors

All papers

Open in search
  1. The classification of glomerulonephritis in systemic lupus erythematosus revisited

    Authors: Jan J. Weening, ON Behalf of the International Society of Nephrology and Renal Pathology Society Working Group on the Classification Oflupus Nephritis, Vivette D. D’Agati, Melvin M. Schwartz, Surya V. Seshan, Charles E. Alpers, Gerald B. Appel, James E. Balow, Jan A. Bruijn, Terence Cook, Franco Ferrario, Agnes B. Fogo, Ellen M. Ginzler, L Hebert, Gary S. Hill, Prue Hill, J. Charles Jennette, Norella Kong, Philippe Lesavre, Michael D. Lockshin, Lai‐Meng Looi, Hirofumi Makino, Luiz A. Moura, Michio Nagata - Kidney International 2004 cited by 1,649

  2. The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited

    Authors: Jan J. Weening, Vivette D. D’Agati, Melvin M. Schwartz, Surya V. Seshan, Charles E. Alpers, Gerald B. Appel, James E. Balow, Jan A. Bruijn, Terence Cook, Franco Ferrario, Agnes B. Fogo, Ellen M. Ginzler, Lee A. Hebert, Gary S. Hill, Prue Hill, J. Charles Jennette, Norella Kong, Philippe Lesavre, Michael D. Lockshin, Lai‐Meng Looi, Hirofumi Makino, Luiz A. Moura, Michio Nagata - Journal of the American Society of Nephrology 2004 cited by 1,998

  3. Enzyme Replacement Therapy in Fabry Disease

    Authors: Raphael Schiffmann, Jeffrey B. Kopp, Howard A. Austin, Sharda G. Sabnis, David F. Moore, Thais Weibel, James E. Balow, Roscoe O. Brady - JAMA 2001 cited by 1,305

  4. Recombinant human Dnase I (rhDNase) in patients with lupus nephritis

    Authors: John C. Davis, S Manzi, Cheryl Yarboro, Joan E. Rairie, Iain B. McInnes, D Averthelyi, Dominick Sinicropi, Victoria Hale, James E. Balow, H A Austin, Dimitrios T. Boumpas, John H. Klippel - Lupus 1999 cited by 233

  5. Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open‐label phase I dosage‐escalation study

    Authors: Gabor G. Illei, Yuko Shirota, Cheryl Yarboro, Jimmy Daruwalla, Edward Tackey, Kazuki Takada, Thomas A. Fleisher, James E. Balow, Peter E. Lipsky - Arthritis & Rheumatism 2010 cited by 505

  6. A short course of BG9588 (anti–CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis

    Authors: Dimitrios T. Boumpas, Richard Furie, Susan Manzi, Gabor G. Illei, Daniel J. Wallace, James E. Balow, Akshay Vaishnaw, on behalf of the BG9588 Lupus Nephritis Trial Group - Arthritis & Rheumatism 2003 cited by 617

  7. Therapy of Lupus Nephritis

    Authors: Howard A. Austin, John H. Klippel, James E. Balow, Nicole G.H. Le Riche, Alfred D. Steinberg, Paul H. Plötz, John L. Decker - New England Journal of Medicine 1986 cited by 1,196

  8. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal‐onset multisystem inflammatory disease (NOMID): A new member of the expanding family of pyrin‐associated autoinflammatory diseases

    Authors: Ivona Aksentijevich, Miroslawa Nowak, Mustapha Mallah, Jae Jin Chae, Wendy T. Watford, Sigrun R. Hofmann, Leonard D. Stein, Ricardo Russo, Donald P. Goldsmith, Peter B. Dent, Helene F. Rosenberg, Frances Austin, Elaine F. Remmers, James E. Balow, Sergio D. Rosenzweig, Hirsh D. Komarow, Nitza G. Shoham, Geryl Wood, Janet H. Jones, Nadira Mangra, Hector Carrero, Barbara S. Adams, Terry L. Moore, Kenneth N. Schikler, Hal M. Hoffman, Daniel J. Lovell, Robert Lipnick, Karyl S. Barron, John J. O’Shea, Daniel L. Kastner, Raphaela Goldbach‐Mansky - Arthritis & Rheumatism 2002 cited by 703

  9. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: Long‐term followup of a cohort of 145 patients participating in randomized controlled studies

    Authors: Gabor G. Illei, Kazuki Takada, Donald Maxwell Parkin, H A Austin, Marianna Crane, Cheryl Yarboro, Ellen M. Vaughan, Takashi Kuroiwa, Carol L. Danning, José M. Morales-De Pando, A D Steinberg, M F Gourley, John H. Klippel, James E. Balow, Dimitrios T. Boumpas - Arthritis & Rheumatism 2002 cited by 332

  10. Glucocorticosteroid Therapy: Mechanisms of Action and Clinical Considerations

    Authors: Anthony S. Fauci, DAVID C. DALE, JAMES E. BALOW - Annals of Internal Medicine 1976 cited by 1,048

  11. Diffuse proliferative lupus nephritis: Identification of specific pathologic features affecting renal outcome

    Authors: Howard A. Austin, Larry R. Muenz, Kathleen Joyce, Tatiana T. Antonovych, James E. Balow - Kidney International 1984 cited by 722

  12. Urinary exosomal transcription factors, a new class of biomarkers for renal disease

    Authors: Hua Zhou, Anita Cheruvanky, Xuzhen Hu, Takayuki Matsumoto, Noriyuki Hiramatsu, Monique E. Cho, Alexandra Berger, Asada Leelahavanichkul, Kent Doi, Lakhmir S. Chawla, Gabor G. Illei, Jeffrey B. Kopp, James E. Balow, Howard A. Austin, Peter S.T. Yuen, Robert A. Star - Kidney International 2008 cited by 277

  13. Glucocorticoid Therapy for Immune-Mediated Diseases: Basic and Clinical Correlates

    Authors: Dimitrios T. Boumpas, George P. Chrousos, Ronald L. Wilder, Thomas R. Cupps, James E. Balow - Annals of Internal Medicine 1993 cited by 779

  14. Methylprednisolone and Cyclophosphamide, Alone or in Combination, in Patients with Lupus Nephritis

    Authors: Mark F. Gourley, Howard A. Austin III, Dorothy Scott, Cheryl H. Yarboro, Ellen M. Vaughan, Joanne Muir, Dimitrios T. Boumpas, John H. Klippel, James E. Balow, Alfred D. Steinberg - Annals of Internal Medicine 1996 cited by 610

  15. Combination Therapy with Pulse Cyclophosphamide plus Pulse Methylprednisolone Improves Long-Term Renal Outcome without Adding Toxicity in Patients with Lupus Nephritis

    Authors: Gabor G. Illei, Howard A. Austin, Marianna Crane, Lee Collins, Mark F. Gourley, Cheryl Yarboro, Ellen M. Vaughan, Takashi Kuroiwa, Carol L. Danning, Alfred D. Steinberg, John H. Klippel, James E. Balow, Dimitrios T. Boumpas - Annals of Internal Medicine 2001 cited by 495

  16. Randomized, Controlled Trial of Prednisone, Cyclophosphamide, and Cyclosporine in Lupus Membranous Nephropathy

    Authors: Howard A. Austin, Gabor G. Illei, Michelle Braun, James E. Balow - Journal of the American Society of Nephrology 2009 cited by 298

  17. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis

    Authors: Dimitrios T. Boumpas, H A Austin, James E. Balow, Ellen M. Vaughan, Cheryl Yarboro, John H. Klippel, A D Steinberg - The Lancet 1992 cited by 827

  18. Prognostic factors in lupus nephritis

    Authors: Howard A. Austin, Larry R. Muenz, Kathleen Joyce, Tatiana A. Antonovych, Margarita E. Kullick, John H. Klippel, John L. Decker, James E. Balow - The American Journal of Medicine 1983 cited by 772

  19. Natural History of Fabry Renal Disease

    Authors: Mary H. Branton, Raphael Schiffmann, Sharda G. Sabnis, Gary J. Murray, Jane M. Quirk, Gheona Altarescu, Lev G. Goldfarb, Roscoe O. Brady, James E. Balow, Howard A. Austin, Jeffrey B. Kopp - Medicine 2002 cited by 462

  20. Chronic granulomatous disease as a risk factor for autoimmune disease

    Authors: Suk See De Ravin, Nora Naumann, Edward W. Cowen, Julia C. Friend, Dianne Hilligoss, Martha Marquesen, James E. Balow, Karyl S. Barron, Maria L. Turner, John I. Gallin, Harry L. Malech - Journal of Allergy and Clinical Immunology 2008 cited by 227

  21. Acyclovir-induced renal failure

    Authors: Mark H. Sawyer, David E. Webb, James E. Balow, Stephen E. Straus - The American Journal of Medicine 1988 cited by 222

  22. Clinical differences between North African and Iraqi Jews with familial Mediterranean fever

    Authors: Eran Pras, Avi Livneh, James E. Balow, Elon Pras, Daniel L. Kastner, Mordechai Pras, Pnina Langevitz - American Journal of Medical Genetics 1998 cited by 283

  23. Treatment of Type B Insulin Resistance: A Novel Approach to Reduce Insulin Receptor Autoantibodies

    Authors: Rana Malek, Angeline Y. Chong, Beatrice Lupsa, Andreea O. Lungu, Elaine Cochran, Maria A. Soos, Robert K. Semple, James E. Balow, Phillip Görden - The Journal of Clinical Endocrinology & Metabolism 2010 cited by 115

  24. miR-150 Promotes Renal Fibrosis in Lupus Nephritis by Downregulating SOCS1

    Authors: Hua Zhou, Sarfaraz Hasni, Paola Pérez, Mayank Tandon, Shyh-Ing Jang, Changyu Zheng, Jeffery B. Kopp, Howard A. Austin, James E. Balow, Ilias Alevizos, Gabor G. Illei - Journal of the American Society of Nephrology 2013 cited by 190